Now with the progressive research and advances in technology, the preclinical diagnosis of AD can be done by recent non-invasive imaging techniques using Aβ- and tau-positron emission tomography (PET) tracers which allow the tracking of the evolution of AD during the patient’s lifetime (Sáez-Orellana et al., 2020). Here, MAPT is linked to Alzheimer disease.